Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis.
OBJECTIVE
To investigate the efficacy of topical cyclosporine A 0.5% as a substitute for corticosteroids in the management of therapeutic keratoplasties for mycotic keratitis.


METHODS
Prospective, nonrandomized interventional case series. Three patients with culture-proven mycotic keratitis underwent therapeutic keratoplasties. All were treated with topical cyclosporine A 0.5% postoperatively as a primary or an adjunctive therapy for prevention of allograft rejection. The patients were followed up from 15 to 42 months for maintenance of graft clarity and best-corrected visual acuity.


RESULTS
Two of three patients maintained clear grafts while using topical cyclosporine A 0.5% twice daily with best-corrected visual acuity of 20/40 and 20/50. One patient developed an opacified graft secondary to preexisting ocular surface disease.


CONCLUSIONS
Topical cyclosporine A 0.5% may be a useful adjunct in the management of therapeutic keratoplasties for mycotic keratitis.
Perry
Henry D
HD
Department of Ophthalmology, North Shore University Hospital, Long Island Jewish Medical Center, Great Neck, New York, U.S.A.
Doshi
Sima J
SJ
Donnenfeld
Eric D
ED
Bai
Grace S
GS
D000287:Administration, Topical; D000368:Aged; D002176:Candida albicans / Q000302:isolation & purification; D003454:Cryptococcus / Q000302:isolation & purification; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D015821:Eye Infections, Fungal / Q000382:microbiology / Q000601:surgery*; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007634:Keratitis / Q000382:microbiology* / Q000601:surgery*; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000382:microbiology / Q000601:surgery*; D011446:Prospective Studies; D011541:Pseudallescheria / Q000302:isolation & purification; D016896:Treatment Outcome; D014792:Visual Acuity
D007166:Immunosuppressive Agents; D016572:Cyclosporine